Product image of Letrozole Eg (Letrozole) supplied by GNH India

Letrozole Eg

Active Ingredient:
Letrozole
Origin:
EU

Letrozole Eg (Letrozole)

Letrozole, the active ingredient in Letrozole Eg, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of hormone receptor‑positive breast cancer in postmenopausal women, reducing estrogen production that can fuel tumor growth.

GNH India supplies Letrozole Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Manufacturer / TM Owner

Eurogenerics N.V./S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Letrozole is an aromatase inhibitor used in the management of estrogen‑dependent breast cancer.

  • Hormone receptor‑positive metastatic breast cancer: reduces tumor progression and improves survival.
  • Adjuvant therapy for early‑stage HR+ breast cancer: lowers risk of disease recurrence.
  • Postmenopausal estrogen‑dependent breast cancer: decreases estrogen levels to inhibit tumor growth.

How It Works

  • Letrozole reversibly binds to the aromatase enzyme, blocking the conversion of androgens to estrogens in peripheral tissues. By inhibiting aromatase, systemic estrogen concentrations fall, depriving estrogen‑dependent tumor cells of a key growth stimulus and thereby slowing or halting disease progression.

Side Effects

Letrozole may cause a range of adverse reactions, most of which are predictable based on its estrogen‑lowering action.

Common Side Effects

  • Hot flashes: sudden feeling of warmth, often with sweating.
  • Joint and muscle pain: aching discomfort in limbs.
  • Fatigue: persistent tiredness not relieved by rest.
  • Nausea: mild to moderate upset stomach.
  • Headache: pressure or throbbing pain.
  • Increased sweating: excessive perspiration.

Serious or Rare Side Effects

  • Severe liver injury: jaundice, elevated liver enzymes.
  • Bone fractures: increased risk due to reduced bone density.
  • Pulmonary embolism: sudden shortness of breath, chest pain.
  • Allergic reactions: rash, swelling, anaphylaxis.
  • Cardiac arrhythmias: QT interval prolongation.
  • Severe osteoporosis: marked loss of bone mineral density.

Precautions & Warnings

Before initiating Letrozole therapy, clinicians should consider several safety measures.

  • Bone health monitoring: assess bone mineral density regularly.
  • Liver function tests: evaluate hepatic enzymes before and during treatment.
  • Cardiovascular assessment: caution in patients with existing heart disease.
  • Avoid use in premenopausal women: drug is not indicated for this population.
  • Drug interaction review: check concomitant medications for potential interactions.
  • Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Letrozole can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce letrozole plasma levels.
  • Estrogen‑containing therapies (e.g., hormone replacement): counteract aromatase inhibition.
  • Strong CYP2C19 inhibitors (e.g., fluoxetine): may increase letrozole exposure.

Moderate Interactions (Monitor Closely)

  • Anticoagulants (warfarin): may require INR monitoring.
  • Statins (e.g., simvastatin): potential increase in statin concentrations.
  • SSRIs (e.g., sertraline): may enhance fatigue or hot flashes.
  • Anticonvulsants (e.g., phenytoin): monitor for altered efficacy.
  • Herbal supplements (e.g., St. John’s wort): possible enzyme induction.

Frequently Asked Questions

Letrozole Eg contains the active ingredient letrozole, an aromatase inhibitor indicated for the treatment of hormone receptor‑positive breast cancer in postmenopausal women. It works by lowering estrogen levels, which can slow or stop the growth of estrogen‑dependent tumors.

Letrozole reversibly inhibits the aromatase enzyme, which is responsible for converting androgens into estrogens in peripheral tissues. By blocking this conversion, systemic estrogen concentrations decrease, depriving estrogen‑dependent cancer cells of a key growth signal.

The specific dose of Letrozole Eg is determined by the prescribing clinician based on the patient’s condition, treatment stage, and overall health. Healthcare professionals set the appropriate dosage and schedule according to current clinical guidelines.

Letrozole is contraindicated in pregnancy because it can interfere with fetal development. It is also not recommended for breastfeeding mothers, as it may pass into breast milk and affect the infant. Women of child‑bearing potential should use effective contraception during treatment.

To request Letrozole Eg, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and any required import documentation.

Letrozole belongs to the class of aromatase inhibitors, which differ from selective estrogen receptor modulators such as tamoxifen. Compared with tamoxifen, letrozole generally provides a greater reduction in estrogen levels and has shown improved disease‑free survival in postmenopausal patients, though side‑effect profiles vary.

Letrozole Eg should be stored at ambient temperature, below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Letrozole Eg is taken orally, usually as a tablet swallowed with water. The medication is typically taken once daily, at the same time each day, unless the prescriber advises a different schedule.

Serious risks include severe liver injury, bone fractures due to decreased bone density, pulmonary embolism, and rare allergic reactions such as anaphylaxis. Patients should be monitored regularly for signs of these conditions, and any concerning symptoms should be reported to a healthcare professional promptly.

Letrozole Eg is not indicated for premenopausal women, pregnant or nursing individuals, and patients with known hypersensitivity to letrozole or any of its excipients. Caution is also advised for patients with severe liver disease, uncontrolled cardiovascular conditions, or those taking interacting medications without proper monitoring.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Letrozole

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT